Compare EHI & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHI | CNTN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.9M | 153.8M |
| IPO Year | 2003 | 2021 |
| Metric | EHI | CNTN |
|---|---|---|
| Price | $5.31 | $1.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 135.7K | ★ 653.1K |
| Earning Date | 01-01-0001 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.20 | $1.66 |
| 52 Week High | $6.55 | $5.27 |
| Indicator | EHI | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 47.32 |
| Support Level | $5.24 | $1.71 |
| Resistance Level | $5.43 | $2.21 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 52.17 | 33.33 |
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income. The Fund's secondary investment objective is total return. It invests in an international portfolio of securities consisting of below-investment-grade fixed income securities, emerging market fixed income securities, and investment-grade fixed income securities. The Fund's investment portfolio comprises sovereign bonds, collateralized mortgage obligations, asset-backed securities, and fixed income securities from different corporate sectors, including financials, energy, consumer discretionary, and industrials, among others.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.